1 completed. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
Follow Undifferentiated Fallopian Tube Carcinoma: new trials by email Literature Review of Undifferentiated Fallopian Tube Carcinoma trials Research Report on Undifferentiated Fallopian Tube Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Bortezomib, Carboplatin, Laboratory Biomarker Analysis - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 33 | 2010-04-05 | 2019-08-09 |
Brenner Tumor (1) · Fallopian Tube Neoplasms (1) · Ovarian Neoplasms (1)
Adnexal Diseases (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Fallopian Tube Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Genital Diseases (1) · Genital Diseases, Female (1) · Genital Neoplasms, Female (1) · Gonadal Disorders (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Connective Tissue (1) · Neoplasms, Connective and Soft Tissue (1)
Bortezomib (1) · Carboplatin (1)
National Cancer Institute (NCI) (1)
United States (1)
Don Dizon (1)
U10CA027469 (1), U10CA180868 (1)